KROS - NASDAQ
Keros Therapeutics, Inc.
$10.77
+2.1%Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
At a Glance
Live SnapshotKeros Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Keros Therapeutics, Inc. Income Statement
KROS • NASDAQ
| Keros Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
244.1M | 3.6M | 151K | 0.0 | 20.1M | 0.0 | 10M | 10M | |
GROSS PROFIT | ||||||||
(1.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (605K) | (17.3M) | (10.1M) | |
242.6M | 3.6M | 151K | 0.0 | 20.1M | -605K | -7.3M | -111K | |
OPERATING INCOME | ||||||||
(171.9M) | (214.4M) | (170.1M) | (114.8M) | (76.5M) | (46.1M) | (20M) | (11.3M) | |
(46.8M) | (40.8M) | (34.8M) | (27.5M) | (21.3M) | (12.2M) | (3.2M) | (1.6M) | |
(129.6M) | (173.6M) | (135.3M) | (87.3M) | (55.1M) | (33.9M) | (17.4M) | (10.1M) | |
70.6M | -210.8M | -169.9M | -114.8M | -56.4M | -46.7M | -10.6M | -1.7M | |
PRE-TAX INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (1K) | (4K) | (6K) | (8K) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | -4K | 0.0 | -8K | 6K | |
-4.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -558K | (237K) | |
21.3M | 23.8M | 16.9M | 10.1M | -360K | 1.1M | -1.8M | 613K | |
91.9M | -187.1M | -153M | -104.7M | -56.7M | -45.5M | -12.3M | -1.1M | |
NET INCOME | ||||||||
(4.9M) | (300K) | (0.0) | (0.0) | (2M) | -172K | (0.0) | (257K) | |
87M | -187.4M | -153M | -104.7M | -58.7M | -45.4M | -12.3M | -1.3M |
SEC Filings
KROS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 20, 2026 | 2026 |
Related Guides
Continue your KROS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.